Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel L, Heinzerling L (2018)


Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 118

Pages Range: 785-792

Journal Issue: 6

DOI: 10.1038/bjc.2017.489

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Hecht, M., Meier, F., Zimmer, L., Polat, B., Loquai, C., Weishaupt, C.,... Heinzerling, L. (2018). Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 118(6), 785-792. https://dx.doi.org/10.1038/bjc.2017.489

MLA:

Hecht, Markus, et al. "Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients." British Journal of Cancer 118.6 (2018): 785-792.

BibTeX: Download